« Back to Record
Citation APA

Bartlett, J. M. S., Poole, C., Shepherd, L., Cardoso, F., Jensen, M. B., Caldas, C., Twelves, C., Rea, D. W., Ejlertsen, B., Leo, A., Pritchard, K., McConkey, C. C., Munro, A., Desmedt, C., Dunn, J. J., Larsimont, D., O'Malley, F. P., Cameron, D. D., & Earl, H. (2015). Predicting anthracycline benefit: TOP2A and CEP17 - Not only but also. Journal of clinical oncology, 33(15), 1680-1687. doi:10.1200/JCO.2013.54.7869


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/217323

Bartlett, J. M. S., Poole, C., Shepherd, L., Cardoso, F., Jensen, M. B., Caldas, C., Twelves, C., Rea, D. W., Ejlertsen, B., Leo, A., Pritchard, K., McConkey, C. C., Munro, A., Desmedt, C., Dunn, J. J., Larsimont, D., O'Malley, F. P., Cameron, D. D., & Earl, H. (2015). Predicting anthracycline benefit: TOP2A and CEP17 - Not only but also. Journal of clinical oncology, 33(15), 1680-1687. doi:10.1200/JCO.2013.54.7869